(Q57450309)

1

0 references

Thomas Schnitzer

2

0 references

Ronald Emkey

3

0 references

Clifford Rosen

5

0 references

Mark Ettinger

6

0 references

Kristel Vandormael

7

0 references

Anastasia Daifotis

Clinical Drug Investigation

8

0 references

publication date

2004

0 references

published in

0 references

volume

24

0 references

issue

6

0 references

page(s)

333-341

0 references

cites work

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

1 reference

12 December 2020

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

1 reference

12 December 2020

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

1 reference

12 December 2020

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

1 reference

12 December 2020

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology

1 reference

12 December 2020

Alendronate for the Treatment of Osteoporosis in Men

1 reference

12 December 2020

Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism

1 reference

12 December 2020

Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?

1 reference

12 December 2020

1 reference

12 December 2020

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

12 December 2020

Management of male osteoporosis: report of the UK Consensus Group

1 reference

12 December 2020

Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

1 reference

12 December 2020

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Undertreatment of osteoporosis in men with hip fracture

1 reference

12 December 2020

Vertebral fracture assessment using a semiquantitative technique.

1 reference

12 December 2020

Risk factors for hip fracture in white men: the NHANES I Epidemiologic Follow-up Study

1 reference

12 December 2020

Prevalence of low serum estradiol levels in male osteoporosis

1 reference

12 December 2020

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

12 December 2020

Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study

1 reference

12 December 2020

Nonlinear kinetics of alendronate. Plasma protein binding and bone uptake.

1 reference

12 December 2020